NASDAQ:TELO
Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. reported net income of −$10.4M in fiscal 2025. The diluted share count rose 7.2%.Summary generated from Telomir Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−317.6%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+7.2%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a |
| Operating income | n/a | n/a | n/a | n/a |
| Net income | −1 | −13 | −17 | −10 |
| Free cash flow | n/a | n/a | n/a | n/a |
Recent filings
- 8-KEntry into a material agreement
Oct 6, 2026 - 8-KRegulation FD disclosure
Sep 17, 2026 - 8-KResults of a shareholder vote
Sep 16, 2026 - 8-KRegulation FD disclosure
Sep 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KRegulation FD disclosure
Aug 10, 2026 - DEF 14AProxy statement
Jul 28, 2026 - 4Insider transaction report
Jul 27, 2026